Core Concept - The price-to-book (P/B) ratio is a key metric for value investors to identify undervalued stocks with potential for exceptional returns, calculated as market price per share divided by book value per share [1][5] Understanding Book Value - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities, calculated by subtracting total liabilities from total assets [3][4] P/B Ratio Insights - A P/B ratio under 1.0 indicates a potentially undervalued stock, while a ratio above 1.0 suggests overvaluation [5][6] - Stocks with low P/B ratios can indicate strong growth prospects, but a low ratio may also reflect weak asset returns or overstated assets [7][8] Screening Parameters for Value Stocks - Stocks should have a P/B ratio lower than the industry median, a P/S ratio below the industry median, and a P/E ratio using F(1) estimates lower than the industry median [11][12] - A PEG ratio under 1 indicates undervaluation relative to growth prospects, and stocks must trade at a minimum price of $5 [13] - High trading volume and favorable Zacks Rank (1 or 2) are also important criteria for screening [14] Identified Low P/B Stocks - Centene Corporation (CNC) has a projected 3-5 year EPS growth rate of 11.5% and holds a Zacks Rank of 2 with a Value Score of A [16] - CVS Health (CVS) has a projected EPS growth rate of 11.4% and also holds a Zacks Rank of 2 with a Value Score of A [16] - The ODP Corporation (ODP) has a projected EPS growth rate of 14% and holds a Zacks Rank of 1 with a Value Score of A [17] - StoneCo (STNE) has a projected EPS growth rate of 25.3% and holds a Zacks Rank of 2 with a Value Score of B [18] - Paysafe Limited (PSFE) has a projected EPS growth rate of 17.9% and holds a Zacks Rank of 1 with a Value Score of A [19]

医疗保险公司Centene下跌35%，创下2006年以来的最大跌幅。 ...

CANADA - 2025/04/06: In this photo illustration, the Centene Corporation logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesCentene Corporation (NYSE:CNC) experienced a challenging Tuesday evening, witnessing a 25% drop in shares during after-hours trading on July 1st. The significant decline in the healthcare giant's stock wasn’t merely another example of market fluctuations; it was di ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.Shares of Centene Corporation CNC fell sharply in today's pre-market trading after the health care company withdrew its guidance for 2025.Centene withdrew its previous 2025 earnings guidance and all underlying guidance elements based on the company's preliminary interpretation of marketplace data from the independent actuarial firm Wakely.Centene shares dipped 27.7% to $40.94 in the pre-market trading session. ...

Core Viewpoint - Centene has withdrawn its 2025 guidance due to lower-than-expected market growth in over 20 states, impacting its risk adjustment revenue expectations significantly [2][3]. Group 1: Market Analysis - An independent actuarial firm's analysis indicated that the overall market growth in 22 states where Centene operates is lower than anticipated, with morbidity levels being significantly higher than the company's previous assumptions [3]. - The analysis covers 22 of the 29 states where Centene sells individual coverage, representing approximately 72% of the company's marketplace membership [3]. Group 2: Financial Impact - Centene's preliminary analysis suggests a reduction in its full-year net risk adjustment revenue transfer expectation by about $1.8 billion, which translates to an adjusted diluted EPS impact of approximately $2.75 [4]. - The estimate is based on paid claims data through April 30, 2025, and includes projections for the remaining eight months of the year [4]. Group 3: Enrollment Trends - Centene's enrollment in Obamacare increased by 29% to 5.6 million members in the first quarter of the year, up from 4.3 million a year ago, despite a decrease of over 330,000 enrollees in Medicaid coverage [4]. Group 4: Legislative Context - The announcement coincides with the U.S. Senate passing a budget bill that could lead to 11 million Americans losing health insurance coverage, primarily affecting those enrolled in Obamacare and Medicaid, which Centene administers [5]. Group 5: Future Reporting - Centene is currently closing its second quarter and analyzing data, with plans to report its second quarter 2025 results and provide further insights on July 25 [6].

Centene shares plunged after the health insurer pulled its 2025 guidance following an early analysis of data from the Affordable Care Act marketplace that showed a significant revenue hit from a risk-sharing mechanism https://t.co/UAPgTjrHd4 ...

Exhibit 99.1 N E W S R E L E A S E Contact: Investor Relations Inquiries Media Inquiries Jennifer Gilligan Isabella Wiltse Senior Vice President, Finance & Investor Relations Vice President, Media & Public Relations (212) 549-1306 (314) 445-0790 FOR IMMEDIATE RELEASE CENTENE CORPORATION REPORTS FIRST QUARTER 2025 RESULTS -- Diluted EPS of $2.63; Adjusted Diluted EPS of $2.90 -- ST. LOUIS, April 25, 2025 -- Centene Corporation (NYSE: CNC) (the Company) announced today its financial results for the first quar ...

Core Viewpoint - Centene Corporation has withdrawn its previous 2025 GAAP and adjusted diluted earnings per share (EPS) guidance due to lower-than-expected market growth and higher morbidity rates in the Health Insurance Marketplace [1][3]. Group 1: Financial Guidance and Market Analysis - The company analyzed 2025 Marketplace data from Wakely, covering 22 of its 29 states, which represents approximately 72% of its Marketplace membership [2]. - The preliminary analysis indicates a reduction in the full year net risk adjustment revenue transfer expectation by approximately $1.8 billion, leading to an adjusted diluted EPS impact of about $2.75 [4]. - The company anticipates further reductions in net risk adjustment revenue transfer expectations for the remaining seven states based on observed morbidity trends [5]. Group 2: Future Pricing and Market Strategy - Centene has begun the process of refiling 2026 Marketplace rates to reflect a higher projected baseline of Marketplace morbidity than previously expected [6]. - The company expects to implement corrective pricing actions for 2026 in states representing a substantial majority of its Marketplace membership [6]. Group 3: Medicaid and Medicare Performance - The Medicaid business has seen a step-up in medical cost trends, particularly in behavioral health, home health, and high-cost drugs, with expectations for a higher Medicaid Health Benefits Ratio (HBR) in Q2 2025 compared to Q1 2025 [8]. - The Medicare Advantage and Medicare Prescription Drug Plan businesses are performing better than expected in Q2 2025, contributing positively to the company's overall financial performance [9]. Group 4: Upcoming Reporting - The company is in the process of closing Q2 2025 and will report results and provide additional insights on July 25, 2025 [10].

Centene (CNC) has been beaten down lately with too much selling pressure. While the stock has lost 5.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price mov ...

Market Overview - Significant turbulence in global financial markets due to escalating hostilities between Israel and Iran, particularly Israeli airstrikes on Iran's nuclear facilities [1] - Major U.S. indices experienced sharp declines, with the Dow Jones Industrial Average down 1.8% (769.81 points), S&P 500 down 1.1% (68.29 points), and Nasdaq Composite down 1.3% (255.67 points) [2] Investment Opportunities - Value stocks may become attractive during market uncertainty as they are often priced below intrinsic value, providing a margin of safety [3] - Effective valuation metric for value stocks is the Price to Cash Flow (P/CF) ratio, with companies like StoneCo Ltd. (STNE), Centene Corporation (CNC), CVS Health Corporation (CVS), and Pfizer Inc. (PFE) showing low P/CF ratios [4][10] Financial Health Metrics - P/CF ratio is preferred over Price/Earnings (P/E) as it reflects a company's financial health by adding back non-cash charges to net income [5][6] - Positive cash flow indicates increased liquidity, allowing companies to settle debts, reinvest, and undertake shareholder-friendly actions [7] Value Investing Strategy - A comprehensive investment strategy should include multiple metrics such as price-to-book ratio, price-to-earnings ratio, and price-to-sales ratio, along with a favorable Zacks Rank and Value Score [8][12] - Parameters for selecting true-value stocks include P/CF less than or equal to industry median, minimum stock price of $5, and various other financial ratios [9][11] Company Performance Insights - StoneCo (STNE) has a Zacks Rank 1, with projected sales and EPS growth of 10.9% and 4.4% respectively, and shares have risen 15.2% in the past year [14] - Centene (CNC) holds a Zacks Rank 2, with projected sales and EPS growth of 10.1% and 1.5% respectively, but shares have declined 19.1% in the past year [14] - CVS Health (CVS) also has a Zacks Rank 2, with projected sales and EPS growth of 3.5% and 12.6% respectively, and shares have increased by 10.4% in the past year [15] - Pfizer (PFE) carries a Zacks Rank 2, with projected sales and EPS declines of 0.6% and 1.6% respectively, and shares have fallen 9.1% in the past year [16]